Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Complete listing of claims:

Claim 1-4 (Cancelled)

5. (Currently amended) The dosage form of Claim ~~1~~23 wherein the at least one agent is a compound having the formula



wherein X is 0 or S; or a pharmaceutically acceptable salt thereof.

Claim 6. (cancelled)

7. (Currently amended) The dosage form of Claim ~~1~~23 wherein the therapeutic agent is sumanirole or a salt thereof and is present in an amount of about 0.05 mg to about 5 mg per dose.

8. (Currently amended) The dosage form of Claim ~~1~~23 wherein the therapeutic agent is (R)-5,6-dihydro-5(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione or a salt thereof and is present in an amount of about 0.05 mg to about 5 mg per dose.

9. (Original) The dosage form of Claim 8 wherein the therapeutic agent is present in an amount of about 0.1 to about 3 mg per dose.

Claims 10-15. (previously cancelled)

Claims 16-22. (cancelled)

23. (Currently amended) A pharmaceutical dosage form comprising (a) an

~~therapeutically or sexual stimulatorily effective~~ amount of about 0.1 mg to about ~~10~~5 mg per dose of a therapeutic agent that comprises at least one compound of formula



or a pharmaceutically acceptable water-soluble salt thereof, said compound or salt thereof being water-soluble, wherein

R^1, R^2 and R^3 are the same or different and are H, C_{1-6} alkyl (optionally phenyl substituted), C_{3-5} alkenyl or alkynyl or C_{3-10} cycloalkyl, or where R^3 is as above and R' and R^2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C_{1-6} alkyl or alkoxy, CN, carboxamide, carboxyl or (C_{1-6} alkyl)carbonyl;

A is CH, CH2, CHF, CHCI, CHBr, CHI, CHCH3, C=O, C=S, CSCH3, C=NH, CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N;

B is CH, CH2, CHF, CHCI, CHBr, CHI, C=O, N, NH or NCH3, and n is 0 or 1; and D is CH, CH2, CHF, CHCI, CHBr, CHI, C=O, O, N, NH or NCH3;

and (b) one or more pharmaceutically acceptable excipients; the dosage form being an oral dosage form selected from the group consisting of fast-melt formulations, breath-freshening pastilles, chewing gums, sublingual tablets, mucoadhesive films and oral strips~~, and having acceptable organoleptic properties~~.

24. (original) The dosage form of Claim 23 wherein the water-soluble compound or salt thereof has a solubility in water at 20-25°C of at least about 10 g/1.

25. (original) The dosage form of Claim 23 wherein the water-soluble compound or salt

thereof is disclosed generically or specifically in U.S. Patent No. 5,273,975.

26-31. (previously cancelled)

32. (previously presented) The dosage form of Claim 23 that dissolves in the mouth without need for drinking water or other fluid.

33. (previously presented) The dosage form of Claim 23 that is a breath-freshening pastille.

34. (previously presented) The dosage form of Claim 23 that is a chewing gum.

35. (previously presented) The dosage form of Claim 23 that is a sublingual tablet.

36. (previously presented) The dosage form of Claim 23 that is a mucoadhesive film.

37. (previously presented) The dosage form of Claim 23 that is an oral strip.

38. (previously presented) The dosage form of Claim 23 that is an oral fast-melt tablet.

39. (withdrawn) A method of treating sexual dysfunction in a subject comprising intraoral administration of a dosage form of Claim 1 to the subject, less than about 1 hour prior to sexual activity.

40. (withdrawn) A method of treating sexual dysfunction in a subject comprising intraoral administration of a dosage form of Claim 23 to the subject, less than about 1 hour prior to sexual activity.

41. (withdrawn) A method of enhancing sexual desire, interest or performance in a subject comprising intraoral administration of a dosage form of Claim 1 to the subject, less than about 1 hour prior to sexual activity.

42. (withdrawn) A method of enhancing sexual desire, interest or performance in a subject comprising intraoral administration of a dosage form of Claim 23 to the subject, less than about 1 hour prior to sexual activity.